News & Views | Published:

PI(3) Kinases

Revealing the delta lady

Nature Chemical Biology volume 6, pages 8283 (2010) | Download Citation

  • A Corrigendum to this article was published on 01 April 2010

This article has been updated

Phosphoinositide 3-OH kinases (PI(3)Ks) are important lipid signaling enzymes and exciting drug targets for a number of human diseases. The first, much anticipated crystal structure of the delta isoform of PI(3)K provides surprising new insights into the selectivity of inhibitors for this versus other PI(3)K isoforms and facilitates the design of improved drugs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 02 March 2010

    In the version of this article initially published, there was an error in the chemical structure of IC87114 that arose from the coordinates used to generate Figure 1a. The corrected structure has been deposited by Berndt et al. to the Protein Data Bank (PDB code 2X38). Figure 1a and the PDB code in the figure legend have been corrected in the HTML and PDF versions of the article.

Accessions

Primary accessions

References

  1. 1.

    et al. Nat. Chem. Biol. 6, 117–124 (2010).

  2. 2.

    & Trends Biotechnol. 27, 315–328 (2009).

  3. 3.

    , , & Nat. Rev. Drug Discov. 8, 627–644 (2009).

  4. 4.

    Science 296, 1655–1657 (2002).

  5. 5.

    , & Trends Biochem. Sci. 32, 450–456 (2007).

  6. 6.

    , , & Cancer Res. (in the press).

  7. 7.

    , , , & Nature 402, 313–320 (1999).

  8. 8.

    et al. Mol. Cell 6, 909–919 (2000).

  9. 9.

    et al. Cell 125, 733–747 (2006).

  10. 10.

    et al. Science 318, 1744–1748 (2007).

  11. 11.

    , , , & J. Immunol. 170, 2647–2654 (2003).

  12. 12.

    et al. Chem. Biol. (in the press).

  13. 13.

    et al. J. Med. Chem. 51, 5522–5532 (2008).

  14. 14.

    et al. Mol. Cancer Ther. 8, 1725–1738 (2009).

  15. 15.

    , & Curr. Opin. Genet. Dev. 19, 12–17 (2009).

Download references

Author information

Affiliations

  1. Paul Workman is in the Cancer Research UK Centre for Cancer Therapeutics and the Section of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK.

    • Paul Workman
  2. Rob L. M. van Montfort is in the Section of Cancer Therapeutics and the Section of Structural Biology, The Institute of Cancer Research, Haddow Laboratories and Chester Beatty Laboratories, Sutton and Chelsea, UK.

    • Rob L M van Montfort

Authors

  1. Search for Paul Workman in:

  2. Search for Rob L M van Montfort in:

Competing interests

P.W. and R.L.M.M. are employees of The Institute of Cancer Research, which has a commercial interest in the development of PI(3)K inhibitors, and operates a rewards-to-inventors scheme. P.W. has been involved in a commercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed Pharma, and intellectual property arising from the program has been licensed to Genentech. P.W. was a scientific founder of, consultant to, and Scientific Advisory Board member of Piramed Pharma; is a scientific founder of, consultant to, and Scientific Advisory Board member and Main Board member of Chroma Therapeutics; and was formerly an employee of AstraZeneca. R.L.M.M. is a former employee of Astex Therapeutics.

Corresponding authors

Correspondence to Paul Workman or Rob L M van Montfort.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nchembio.305

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing